Results 21 to 30 of about 110,790 (277)

Borrelia valaisiana resist complement-mediated killing independently of the recruitment of immune regulators and inactivation of complement components [PDF]

, 2013
Spirochetes belonging to the Borrelia (B.) burgdorferi sensu lato complex differ in their resistance to complement-mediated killing, particularly in regard to human serum.
A Alitalo, A Alitalo, A Alitalo, A Seling, AC Steere, AM Blom, Andreas Klos, AP van Dam, B Stevenson, C Hammerschmidt, C Siegel, C Siegel, Christine Skerka, Claudia Hammerschmidt, CS Brooks, Dania Richter, E Diza, F Strle, Franz-Rainer Matuschka, H Jiang, H Michel, J Hellwage, J Pietikainen, J Potempa, Jasmin Schwab, JD Lambris, JV McDowell, K Hartmann, K Haupt, K Kurtenbach, K Kurtenbach, K Saito, K Whaley, KM Hovis, KP Hunfeld, L Beinrohr, M Collares-Pereira, M Jusko, M Józsi, MJ Walport, MK Pangburn, MR Bhide, MR Bhide, MR Kenedy, MS Metts, N Marr, ND van Burgel, P Herzberger, P Herzberger, P Kraiczy, P Kraiczy, P Kraiczy, P Kraiczy, P Kraiczy, P Kraiczy, P Ramu, Peter F. Zipfel, Peter Kraiczy, PF Zipfel, PF Zipfel, R Dieterich, R Wallich, Reinhard Wallich, RG Discipio, RJ Ziccardi, S Breitner-Ruddock, S Grosskinsky, S Grosskinsky, S Heinen, S Kühn, SC Bock, SG Rijpkema, SH Rooijakkers, T Fujita, T Fujita, V Brade, Y Terao   +76 more
core   +11 more sources

Complement Component 5 (C5) Deficiency Improves Cognitive Outcome After Traumatic Brain Injury and Enhances Treatment Effects of Complement Inhibitors C1-Inh and CR2-Crry in a Mouse Model

Neurotrauma Reports, 2023
A potent effector of innate immunity, the complement system contributes significantly to the pathophysiology of traumatic brain injury (TBI). This study investigated the role of the complement cascade in neurobehavioral outcomes and neuropathology after ...
Min Chen, Stephen R. Edwards, Dhiraj Maskey, Trent M. Woodruff, Stephen Tomlinson, David Reutens   +5 more
doaj   +1 more source

Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.

PLoS ONE, 2020
Complement is a key component of the innate immune system. Inappropriate complement activation underlies the pathophysiology of a variety of diseases. Complement component 5 (C5) is a validated therapeutic target for complement-mediated diseases, but the
Adrianna Latuszek, Yashu Liu, Olav Olsen, Randi Foster, Marc Cao, Irena Lovric, Ming Yuan, Nina Liu, Henry Chen, Qian Zhang, Hui Xiao, Carola Springer, George Ehrlich, Vishal Kamat, Ashique Rafique, Ying Hu, Pamela Krueger, Tammy Huang, William Poueymirou, Robert Babb, Michael P Rosconi, Marc W Retter, Gang Chen, Lori Morton, Brian Zambrowicz, Jingtai Cao, Carmelo Romano, William C Olson   +27 more
doaj   +1 more source

Shiga Toxin 2a Binds to Complement Components C3b and C5 and Upregulates Their Gene Expression in Human Cell Lines

Toxins, 2020
Enterohemorrhagic Escherichia coli (EHEC) infections can cause EHEC-associated hemolytic uremic syndrome (eHUS) via its main virulent factor, Shiga toxins (Stxs). Complement has been reported to be involved in the progression of eHUS.
Sára Kellnerová, Sneha Chatterjee, Rafael Bayarri-Olmos, Louise Justesen, Heribert Talasz, Wilfried Posch, Samyr Kenno, Peter Garred, Dorothea Orth-Höller, Marco Grasse, Reinhard Würzner   +10 more
doaj   +1 more source

Complement-5 Inhibition Deters Progression of Fulminant Hepatitis to Acute Liver Failure in Murine ModelsSummary

Cellular and Molecular Gastroenterology and Hepatology, 2021
Background & Aims: Acute liver failure (ALF) is a life-threatening condition with limited treatment alternatives. ALF pathogenesis seemingly involves the complement system. However, no complement-targeted intervention has been clinically applied.
Jiro Kusakabe, Koichiro Hata, Hidetaka Miyauchi, Tetsuya Tajima, Yi Wang, Ichiro Tamaki, Junya Kawasoe, Yusuke Okamura, Xiangdong Zhao, Tatsuya Okamoto, Tatsuaki Tsuruyama, Shinji Uemoto   +11 more
doaj   +1 more source

In vaccinated individuals serum bactericidal activity against B meningococci is abrogated by C5 inhibition but not by inhibition of the alternative complement pathway

Frontiers in Immunology, 2023
IntroductionSeveral diseases caused by the dysregulation of complement activation can be treated with inhibitors of the complement components C5 and/or C3.
Emma Ispasanie, Emma Ispasanie, Lukas Muri, Lukas Muri, Marc Schmid, Marc Schmid, Anna Schubart, Christine Thorburn, Natasa Zamurovic, Thomas Holbro, Michael Kammüller, Gerd Pluschke, Gerd Pluschke   +12 more
doaj   +1 more source

Hyperfunctional complement C3 promotes C5-dependent atypical hemolytic uremic syndrome in mice [PDF]

, 2019
Atypical hemolytic uremic syndrome (aHUS) is frequently associated in humans with loss-of-function mutations in complement-regulating proteins or gain-of-function mutations in complement-activating proteins.
Atkinson, John P, Barlow, Paul N, Cook, H. T, Cooke, Katie, Denton, Harriet, Kavanagh, David, Liszewski, M. K, Marchbank, Kevin J, Pappworth, Isabel Y, Pickering, Matthew C, Smith-Jackson, Kate, Yang, Yi   +11 more
core   +3 more sources

Differential Surface Deposition of Complement Proteins on Logarithmic and Stationary Phase Leishmania Chagasi Promastigotes [PDF]

, 2012
Previous works demonstrated that various species of Leishmania promastigotes exhibit differential sensitivity to complement-mediated lysis (CML) during development.
Beetham, Jeffrey, Beetham, Jeffrey, Bellaire, Bryan, Lei, Soi Meng, Ramer-Tait, Amanda   +4 more
core   +3 more sources

Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis

Molecular Therapy: Methods & Clinical Development, 2019
Complement-mediated damage to the neuromuscular junction (NMJ) is a key mechanism of pathology in myasthenia gravis (MG), and therapeutics inhibiting complement have shown evidence of efficacy in the treatment of MG.
Linda L. Kusner, Kristina Yucius, Manjistha Sengupta, Andrew G. Sprague, Dhruv Desai, Tuyen Nguyen, Klaus Charisse, Satya Kuchimanchi, Rajeev Kallanthottathil, Kevin Fitzgerald, Henry J. Kaminski, Anna Borodovsky   +11 more
doaj   +1 more source

C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy [PDF]

, 2016
Introduction Guillain-Barré syndrome (GBS) is an autoimmune disease that results in acute paralysis through inflammatory attack on peripheral nerves, and currently has limited, non-specific treatment options.
Barrie, Jennifer A., Cunningham, Madeleine E., Fewou, Simon N., Furukawa, Koichi, McGonigal, Rhona, Sankaranarayanan, Sethu, Willison, Hugh J., Yao, Denggao, Yednock, Ted A.   +8 more
core   +2 more sources